NVCR
NovoCure Ltd.
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$14.89
+5.83%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$14.14
From 52W high−25.51%
Volume1.55M
Market cap$1.73B
P/E (TTM)—
P/S (TTM)2.5x
Div yield—
Key dataOct 19, 2026
Open
$14.14
From 52W high
−25.51%
Volume
1.55M
Market cap
$1.73B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−11.5x
P/E (TTM)
—
RSI (14)
45.2
MomentumView details →
1D Return
+5.83%
YTD Return
+14.62%
SummaryUpdated Jun 1, 2026
NovoCure Limited (NASDAQ:NVCR) is a Jersey-incorporated oncology company founded in 2000 that has developed a novel cancer treatment technology called Tumor Treating Fields (TTFields). The company went public in 2015 and has since established itself as a pioneer in delivering electric field therapy for solid tumor cancers. NovoCure operates globally with commercial presence in the United States, Europe, Japan, and other international markets, focusing on bringing its unique non-invasive treatment modality to cancer patients worldwide.
Similar companies
Latest newsMore news →